U.S. Stem Cell (USRM) 10-Q 8 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 08, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	U.S. STEM CELL, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		59,573,684
Amendment Flag	false
Entity Central Index Key	1,388,319
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	Yes
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 245,991	$ 58,372
Accounts receivable, net	33,858	35,032
Inventory	40,414	17,406
Prepaid and other	0	4,832
Total current assets	320,263	115,642
Property and equipment, net	22,827	14,172
Other assets
Investments	60,066	89,139
Deposits	10,160	10,160
Total assets	413,316	229,113
Current liabilities:
Accounts payable, including $93,932 and $104,089 to related parties, respectively	1,362,832	1,503,501
Accrued expenses	871,027	726,751
Advances, related party	104,901	106,505
Deferred revenue	98,699	71,961
Deposits	465,286	465,286
Promissory note, short term portion, net of debt discount of $73,032 and $78,864 respectively	76,968	71,136
Notes payable, related party	2,453,696	1,727,022
Notes payable, net of debt discount of $203,021 and $249,205, respectively	753,974	608,502
Derivative liabilities	772,108	423,927
Total current liabilities	6,959,491	5,704,591
Long term debt:
Promissory note, long term portion, net of debt discount of $186,687 and $240,522, respectively	1,211,075	1,232,241
Notes payable, long term portion	982,777	983,727
Note payable, long term portion, related party	0	30,000
Total long term debt	2,193,852	2,245,968
Total liabilities	9,153,343	7,950,559
Commitments and contingencies	0	0
Stockholders' deficit:
Preferred stock, par value $0.001; 20,000,000 shares authorized, 20,000,000 issued and outstanding	20,000	20,000
Common stock, par value $0.001; 2,000,000,000 shares authorized, 29,213,395 and 1,813,689 shares issued and 29,213,395 and 1,728,478 outstanding as of September 30, 2016 and December 31, 2015, respectively	29,213	1,814
Additional paid in capital	115,683,769	114,555,110
Treasury stock, 85,211 shares	0	(221,996)
Accumulated deficit	(124,473,009)	(122,076,374)
Total stockholders' deficit	(8,740,027)	(7,721,446)
Total liabilities and stockholders' deficit	$ 413,316	$ 229,113

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parentheticals) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Accounts payable, related parties (in Dollars)	$ 93,932	$ 104,089
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	20,000,000	20,000,000
Preferred stock, shares outstanding	20,000,000	20,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	29,213,395	1,813,689
Common stock, shares outstanding	29,213,395	1,728,478
Treasury stock, shares		85,211
Loans Payable [Member]
Debt discount (in Dollars)	$ 203,021	$ 249,205
Current Portion [Member] | Notes Payable, Other Payables [Member]
Debt discount (in Dollars)	73,032	78,864
Long Term Portion [Member] | Notes Payable, Other Payables [Member]
Debt discount (in Dollars)	$ 186,687	$ 240,522

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue:
Products	$ 345,274	$ 321,129	$ 1,211,609	$ 949,251
Services	384,539	236,483	907,372	663,225
Total revenue	729,813	557,612	2,118,981	1,612,476
Cost of sales	332,522	243,940	722,276	841,511
Gross profit	397,291	313,672	1,396,705	770,965
Cost and operating expenses:
Research and development	1,847	12,764	9,313	39,696
Marketing, general and administrative	1,413,929	563,676	2,676,415	2,279,288
Depreciation and amortization	1,501	1,328	3,926	3,947
Total operating expenses	1,417,277	577,768	2,689,654	2,322,931
Net loss from operations	(1,019,986)	(264,096)	(1,292,949)	(1,551,966)
Other income (expenses):
(Loss) gain on settlement of debt	(23,133)	58,873	49,681	2,097,483
Gain on disposal of equipment	0	0	500	0
(Loss) gain on change of fair value of derivative liability	(413,217)	374,684	(269,822)	260,953
Income from equity investment	54,729	11,625	85,927	23,934
Other income	0	10,131	24,741	13,282
Interest expense	(278,798)	(312,576)	(994,713)	(1,126,668)
Total other income (expenses)	(660,419)	142,737	(1,103,686)	1,268,984
Net loss before income taxes	(1,680,405)	(121,359)	(2,396,635)	(282,982)
Income taxes (benefit)	0	0	0	0
NET LOSS	$ (1,680,405)	$ (121,359)	$ (2,396,635)	$ (282,982)
Net loss per common share, basic and diluted (in Dollars per share)	$ (0.09)	$ (0.15)	$ (0.28)	$ (0.38)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	18,289,275	835,113	8,628,866	736,269

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) - 9 months ended Sep. 30, 2016 - USD ($)	Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]Common Stock [Member]	Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]Additional Paid-in Capital [Member]	Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]	Common Stock Issued in Settlement of Other Debt [Member]Common Stock [Member]	Common Stock Issued in Settlement of Other Debt [Member]Additional Paid-in Capital [Member]	Common Stock Issued in Settlement of Other Debt [Member]	Common Stock Issue dfor Settlement of Related Party Advances [Member]Common Stock [Member]	Common Stock Issue dfor Settlement of Related Party Advances [Member]Additional Paid-in Capital [Member]	Common Stock Issue dfor Settlement of Related Party Advances [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2015										$ 20,000	$ 1,814	$ 114,555,110	$ (221,996)	$ (122,076,374)	$ (7,721,446)
Balance (in Shares) at Dec. 31, 2015										20,000,000	1,813,689
See the accompanying notes to these unaudited condensed financial statements
Common stock issued settlement of debt	$ 1,420	$ 102,096	$ 103,516	$ 26,060	$ 919,358	$ 945,418	$ 14	$ 6,558	$ 6,572
Common stock issued settlement of debt (in Shares)	1,419,675			26,060,886			14,606
Purchase of 10,250 shares of Company's common stock at average cost of $0.76 per share													(7,817)		(7,817)
Treasury shares canceled and returned to authorized											$ (95)	(229,718)	229,813
Treasury shares canceled and returned to authorized (in Shares)											(95,461)
Change in fair value of repriced employee stock options												934			934
Stock based compensation												329,431			329,431
Net loss														(2,396,635)	(2,396,635)
Balance at Sep. 30, 2016										$ 20,000	$ 29,213	$ 115,683,769	$ 0	$ (124,473,009)	$ (8,740,027)
Balance (in Shares) at Sep. 30, 2016										20,000,000	29,213,395

CONDENSED STATEMENT OF STOCKHO6

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) (Parentheticals) - Common Stock [Member]	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Purchase of Company's Common Stock, Shares | shares	10,250
Purchase of Company's Common Stock, Average Cost Per Share | $ / shares	$ 0.76

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,396,635)	$ (282,982)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,926	3,947
Bad debt expense	21,204	0
Discount on convertible debt	556,910	612,811
Change in fair value of derivative liability	269,822	(260,953)
Gain on settlement of debt	(49,681)	(2,097,483)
Gain on sale of equipment	(500)	0
Common stock issued in settlement of litigation	0	59,850
Related party notes payable issued for services rendered	800,000	0
Non-cash payment of interest	193,946	227,396
Income on equity investments	(85,927)	(23,934)
Stock based compensation	329,431	341,629
Change in fair value of repriced employee options	934	0
(Increase) decrease in:
Receivables	(20,030)	1,639
Inventory	(23,008)	0
Prepaid and other current assets	4,832	100
Increase (decrease) in:
Accounts payable	78,504	324,026
Accrued expenses	176,102	272,322
Deferred revenue	26,738	32,170
Net cash used in operating activities	(113,432)	(789,462)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from (payments to) equity investments	115,000	(10,000)
Proceeds from sale of property and equipment	500	0
Purchase of treasury stock	(7,817)	(157,664)
Acquisitions of property and equipment	(12,581)	(894)
Net cash provided by (used in) investing activities	95,102	(168,558)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net	0	582,808
Proceeds from notes payable	523,089	541,410
Net proceeds from related party advances	15,000	6,604
Repayments of related party notes	(103,326)	0
Repayments of notes payable	(228,814)	(143,818)
Net cash provided in financing activities	205,949	987,004
Net increase in cash and cash equivalents	187,619	28,984
Cash and cash equivalents, beginning of period	58,372	36,674
Cash and cash equivalents, end of period	245,991	65,658
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	49,214	273,883
Income taxes paid	0	0
Non-cash financing activities:
Promissory note issued in exchange for subordinated debt and accrued expenses	0	1,697,762
Common Stock Issued in Settlement of Notes Payable [Member]
Non-cash financing activities:
Non-cash financing activities, stock issued	385,710	623,237
Common Stock Issued in Settlement of Accounts Payable [Member]
Non-cash financing activities:
Non-cash financing activities, stock issued	103,516	165,412
Common Stock Issued in Settlement of Related Party Notes and Advances Payable [Member]
Non-cash financing activities:
Non-cash financing activities, stock issued	10,000	0
Common Stock Issued in Settlement of Guarantor Fees [Member]
Non-cash financing activities:
Non-cash financing activities, stock issued	$ 0	$ 170,101

NOTE 1 - SIGNIFICANT ACCOUNTING

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 1 — SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed financial statements follows: General The accompanying unaudited condensed financial statements of U.S. Stem Cell, Inc., (the “Company”), have been prepared in accordance with the rules and regulations (Regulation S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three and nine month periods ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ended December 31, 2016. The unaudited condensed financial statements should be read in conjunction with the December 31, 2015 audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K. Basis and business presentation U.S. Stem Cell, Inc. was incorporated under the laws of the State of Florida in August, 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine/cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. To date, the Company has not generated significant sales revenues in that they remain less than their total operating expenses, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a research and development business enterprise. Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client. The Company’s primary sources of revenue are from the sale of test kits and equipment, training services, patient treatments and laboratory services, and cell banking. Revenues for kits and equipment sold are not recorded until kits and equipment are shipped. Revenues from trainings are recognized when the training occurs. Any cash received as a deposit for trainings are recorded by the company as a liability. Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for cell banking sales are accounted for as Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Because the Company sells its services separately, on more than a limited basis and at a price within a narrow range, the Company was able to allocate revenue based on vendor-specific objective evidence of fair value (VSOE). At September 30, 2016 and December 31, 2015, the Company had deferred revenues of $98,699 and $71,961, respectively. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Allowance for Doubtful Accounts Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of September 30, 2016 and December 31, 2015, allowance for doubtful accounts was $15,306 and $-0-, respectively. Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs. Investments The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 33 percent ownership of U.S. Stem Cell Clinic, LLC utilizing the equity method of accounting. (See Note 3) Stock based compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of September 30, 2016, there were outstanding stock options to purchase 23,555,777 shares of common stock, 8,376,579 shares of which were vested. Net Loss per Share The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period, adjusted to give effect to the 1,000-for-1 reverse stock split, which was effective in the market on November 5, 2015. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share for the three and nine months ended September 30, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2016 September 30, 2015 Convertible debt 147,287,847 371,441 Series A convertible preferred stock 20,000,000 20,000,000 Options to purchase common stock 23,555,777 73,804 Warrants to purchase common stock 139,145 138,739 Totals 190,982,769 20,583,984 Treasury Stock The Company uses the cost method when it purchases its own common stock as treasury shares and displays treasury stock as a reduction of shareholders’ equity. Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. As of September 30, 2016, five customers represented 22%, 18%, 13%, 10% and 10%, respectively, representing an aggregate of 73% of the Company’s accounts receivable. As of December 31, 2015, three customers represented 32%, 18% and 16% respectively, representing an aggregate of 66% of the Company’s accounts receivable. For the three months ended September 30, 2016, the Company’s revenues earned from the sale of products and services were $729,813, of which one customer represented 18% of the Company’s revenues. For the three months ended September 30, 2015, the Company’s revenues earned from the sale of products and services were $557,612, of which one customer represented 11% of the Company’s revenues. For the nine months ended September 30, 2016, the Company’s revenues earned from the sale of products and services were $2,097,341, of which one customer represented 13% of the Company’s revenues. For the nine months ended September 30, 2015, the Company’s revenues earned from the sale of products and services were $1,612,476, of which no customers represented 10% or more of the Company’s revenues. Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $1,847 and $9,313 for the three and nine months ended September 30, 2016, respectively; and $12,764 and $39,696 for the three and nine months ended September 30, 2015, respectively. Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2016 and December 31, 2015, the Company did not have any derivative instruments that were designated as hedges. At September 30, 2016 and December 31, 2015, the Company had outstanding convertible notes and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 6 and Note 8). Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. Recent Accounting Pronouncements There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows. Reclassification Certain reclassifications have been made to prior periods’ data to conform to the current year’s presentation. These reclassifications had no effect on reported income or losses. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.

NOTE 2 - GOING CONCERN AND MANA

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements during nine months ended September 30, 2016, the Company incurred net losses of $2,396,635 and used $113,432 in cash for operating activities. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time. The Company's primary source of operating funds in 2015 and 2016 has been from revenue generated from sales with additional cash proceeds from the sale of common stock and the issuance of convertible and other debt. The Company has experienced net losses and negative cash flows from operations since inception, but expects these conditions to improve in 2016 and beyond as it develops its business model. The Company has stockholders' deficiencies at September 30, 2016 and requires additional financing to fund future operations. The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

NOTE 3 - INVESTMENTS

NOTE 3 - INVESTMENTS	9 Months Ended
	Sep. 30, 2016
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 3 — INVESTMENTS The investment recorded is comprised of a 33% ownership of U.S. Stem Cell Clinic, LLC, accounted for using the equity method of accounting. The investments in 2014 and 2015 of cash and expenses paid on U.S. Stem Cell Clinic, LLC’s behalf were in aggregate of $59,714. The Company’s 33% income earned by U.S. Stem Cell Clinic, LLC of $54,729 and $85,927 for the three and nine months ended September 30, 2016 respectively; and $11,625 and $23,934 for the three and nine months ended September 30, 2015, respectively, (inception to date income of $115,352) was recorded as other income/expense in the Company’s Statement of Operations in the appropriate periods. In addition, during the nine months ended September 30, 2016, the Company received distributions totaling $115,000 from U.S. Stem Cell Clinic, LLC. The carrying value of the investment at September 30, 2016 was $60,066. At September 30, 2016 and December 31, 2015, accounts receivable for sales of test kits to U.S. Stem Cell Clinic, LLC was $9,280 and $5,946 respectively; revenues earned from sales to U.S. Stem Clinic, LLC for the three and nine months ended September 30, 2016 were $142,774 and $303,625 respectively; and for the three and nine months ended September 30, 2015 were $63,989 and $124,484, respectively.

NOTE 4 - PROPERTY AND EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 — PROPERTY AND EQUIPMENT Property and equipment as of September 30, 2016 and December 31, 2015 is summarized as follows: September 30, 2016 December 31, 2015 (audited) Laboratory and medical equipment $ 342,218 $ 353,253 Furniture, fixtures and equipment 130,410 130,410 Computer equipment 48,788 48,788 Leasehold improvements 362,046 362,046 883,462 894,497 Less accumulated depreciation and amortization (860,635 ) (880,325 ) $ 22,827 $ 14,172 Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives. During the nine months ended September 30, 2016, the Company sold fully depreciated equipment for net proceeds (and gain) of $500. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment in accordance with the guidance for impairment of long lived assets.

NOTE 5 - ACCRUED EXPENSES

NOTE 5 - ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2016
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 5 — ACCRUED EXPENSES Accrued expenses consisted of the following as of September 30, 2016 and December 31, 2015: September 30, 2016 December 31, 2015 (audited) Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest $ 131,506 $ 64,199 Interest payable on notes payable 563,174 467,664 Vendor accruals and other 146,429 147,244 Employee commissions, compensation, etc. 29,918 47,644 $ 871,027 $ 726,751 During the nine months ended September 30, 2016, the Company issued an aggregate of 1,419,675 shares of its common stock in settlement of outstanding accounts payable and accrued expenses. In connection with the issuance, the Company incurred $134,967 net gain in settlement of debt.

NOTE 6 - NOTES PAYABLE

NOTE 6 - NOTES PAYABLE	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 6 — NOTES PAYABLE Promissory notes payable were comprised of the following as of September 30, 2016 and December 31, 2015: September 30, 2016 December 31, 2015 (audited) Seaside Bank note payable. $ 980,000 $ 980,000 Hunton & Williams notes payable 384,972 384,972 Daniel James Management notes payable 50,000 75,000 Fourth Man, LLC notes payable 100,000 77,450 Magna Group notes payable 179,240 125,000 Power Up Lending Group notes payable 241,650 194,235 Equipment finance lease 3,910 4,777 Total notes payable 1,939,772 1,841,434 Less unamortized debt discount (203,021 ) (249,205 ) Total notes payable net of unamortized debt discount 1,736,751 1,592,229 Less current portion (753,974 ) (608,502 ) Long term portion $ 982,777 $ 983,727 Seaside Bank On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain shareholders of the Company. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2016 to extend the maturity date to January 11, 2018. Hunton & Williams Notes At September 30, 2016 and December 31, 2015, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822, are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off. Daniel James Management (during this period) 2016 Notes During the nine months ended September 30, 2016, the Company entered into Securities Purchase Agreements with Daniel James Management (“Daniel”) for the sale of 9.5% convertible promissory note in aggregate principal amount of $75,000 (the “Daniel Notes”). The Daniel Notes bear interest at the rate of 9.5% per annum. As of the nine months ended September 30, 2016, all interest and principal must be repaid one year from the issuance date, with the last note being due March 9, 2017. The Daniel Notes are convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Daniel Notes. These embedded derivatives included certain conversion features and reset provision. (See Note 8). The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Daniel Notes and to fair value as of each subsequent reporting date which at September 30, 2016 was $126,304. At the inception of the Daniel Notes, the Company determined the aggregate fair value of $139,691 of the embedded derivatives. During the nine months ended September 30, 2016, $75,000 of promissory notes plus accrued interest that were outstanding at December 31, 2015 and $25,000 of promissory notes plus interest issued in the current period were converted into shares of the Company’s common stock, respectively (see Note 9). The remaining aggregate promissory notes to Daniel unconverted principle balance as of September 30, 2016 was $50,000. Fourth Man (during this period) During the nine months ended September 30, 2016, the Company entered into Securities Purchase Agreements with Fourth Man, LLC (“Fourth Man”) for the sale of 9.5% convertible promissory note in aggregate principal amount of $100,000 (the “Fourth Man Notes”). The Fourth Man Notes bear interest at the rate of 9.5% per annum. As of the nine months ended September 30, 2016, all interest and principal must be repaid one year from the issuance date, with the last note being due September 19, 2017. The Fourth Man Notes are convertible into common stock, at holder’s option, at a 49% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. The Company has identified the embedded derivatives related to the Fourth Man Notes. These embedded derivatives included certain conversion features and reset provision. (See Note 8). The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Fourth Man Notes and to fair value as of each subsequent reporting date which at September 30, 2016 was $286,415. At the inception of the Fourth Man Notes, the Company determined the aggregate fair value of $216,050 of the embedded derivatives. During the nine months ended September 30, 2016, $77,450 of promissory notes plus accrued interest that were outstanding at December 31, 2015 were converted into shares of the Company’s common stock (see Note 9). The remaining aggregate promissory notes to Fourth Man unconverted principle balance as of September 30, 2016 was $100,000. Magna Group (during this period) 2015 Note On December 3, 2015, the Company entered into a Securities Purchase Agreement with Magna Equities II, LLC (“Magna”) for the sale of a 12% convertible promissory note in the principal amount of $262,500 (the “Note”). The Note was subsequently funded in February 2016 upon effectiveness of the Company’s registration statement (see below). Proceeds from the Note was $250,000 (less an original issue discount of 5% or $12,500). The Note bears interest at the rate of 12% per annum. All interest and principal must be repaid on December 3, 2016. The Note is convertible into common stock, at Magna’s option, at the lower of I) 40% discount to the lowest sales price of the common stock during the 5 trading day period prior to conversion or ii) $0.70. In the event the Company prepays the Note in full, the Company is required to pay off all principal at 140%, interest and any other amounts. On December 12, 2014, the Company filed a Registration Statement on Form S-1 to register 341,718 shares of common issuable upon the conversion of Magna Equity II, LLC convertible notes dated December 3, 2015 (as restated) for $110,000 and December 3, 2015 for $262,500. The latter note was funded in February 2016. The Registration Statement on Form S-1 was declared effective on February 12, 2016 The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of Notes to Magna and to fair value as of each subsequent reporting date which at September 30, 2016 was $359,301. At the inception of the Notes, the Company determined the aggregate fair value of $263,204 of the embedded derivatives. During the nine months ended September 30, 2016, $208,260 of the promissory notes were converted into shares of the Company’s common stock (see Note 9). The remaining aggregate Magna Group promissory notes unconverted principle balance as of September 30, 2016 was $179,240. PowerUp Lending Group, Ltd (during this period) On March 23, 2016, the Company entered into a revenue based factoring agreement and received an aggregate of $200,000 (less origination fees of $1,650) in exchange for $276,000 of future receipts relating to monies collected from customers or other third party payors. Under the terms of the agreement, the Company is required to make daily payments equal to $1,314 for 210 business days. The Company received net proceeds of $82,896 along with cancellation of the previous revenue based factoring agreement issued in 2015. In connection with the cancellation of the December 2015 revenue based factoring agreement, the Company incurred a loss in settlement of debt of $39,449. On August 16, 2016, the Company entered into a revenue based factoring agreement and received an aggregate of $210,000 (less origination fees of $2,000) in exchange for $283,500 of future receipts relating to monies collected from customers or other third party payors. Under the terms of the agreement, the Company is required to make daily payments equal to $1,350 for 210 business days. The Company received net proceeds of $65,193 along with cancellation of the previous revenue based factoring agreement issued on March 23, 2016. In connection with the cancellation of the March 2016 revenue based factoring agreement, the Company incurred a loss in settlement of debt of $49,264. The remaining principle balance of the PowerUp Lending Group promissory note payable at September 30, 2016 is $241,650. At September 30, 2016, the Company has recorded interest expense in the amount of $10,775 under the terms of the agreement. The remaining unamortized debt discount at September 30, 2016 is $64,725. Promissory note On June 1, 2015, the Company issued an amended and restated promissory note of $1,697,762 in settlement of the $1,500,000 outstanding subordinated debt, related accrued interest of $373,469 and accumulated and unpaid guarantor fees of $624,737. The note is unsecured and non-interest bearing with four semi-annual payments of $75,000 beginning on December 31, 2015 with the remaining unpaid balance due June 1, 2020. The Company imputed an interest rate of 5% and discounted the promissory note accordingly. The imputed debt discount of $368,615 is amortized to interest expense using the effective interest method. For the three and nine months ended September 30, 2016, the Company amortized $19,506 and $59,666 of debt discounts to current period operations as interest expense, respectively. The unamortized debt discount at September 30, 2016 is $259,719. During 2016, the Company made principle payments of $75,000 on the promissory note. As of September 30, 2016, the remaining principle due was $1,547,762. Summary: The Company has identified the embedded derivatives related to the Daniel, Fourth Man and Magna promissory notes. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of these notes and to fair value as of each subsequent reporting date which at September 30, 2016 was $772,020. The fair value of the embedded derivatives at issuance of the Daniel, Fourth Man and Magna promissory notes, were determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 178.42% to 213.94%, (3) weighted average risk-free interest rate of 0.45% to 0.69%, (4) expected lives of 0.79 to 1.00 years, and (5) estimated fair value of the Company’s common stock from $0.0145 to $0.9342 per share. The initial fair value of the embedded debt derivative of $618,946 was allocated as a debt discount up to the proceeds of the notes ($425,000) with the remainder ($193,946) charged to current period operations as interest expense. For the three and nine months ended September 30, 2016, the Company amortized an aggregate of $138,721 and $497,244 of debt discounts to current period operations as interest expense, respectively.

NOTE 7 - RELATED PARTY TRANSACT

NOTE 7 - RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 7 — RELATED PARTY TRANSACTIONS Advances As of September 30, 2016 and December 31, 2015, the Company’s officers and directors have provided advances in the aggregate of $104,901 and $106,505 respectively, for working capital purposes. The advances are unsecured, due on demand and non-interest bearing. On February 12, 2016, the Company issued 14,606 shares of its common stock in settlement of $10,000 of the outstanding advances due. In connection with the settlement, the Company realized a net gain on settlement of debt of $3,427. Notes payable-related party Northstar Biotechnology Group, LLC On February 29, 2012, a promissory note issued to BlueCrest Master Fund Limited was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267 the (“Note”). On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock. On September 21, 2012, the Company issued 5,000 common stock purchase warrants to Northstar that was treated as additional interest expense upon issuance. On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights. In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated. Effective October 1, 2012, the effective interest rate was 12.85% per annum. The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum. In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued, which was subsequently increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. In addition, the Company is The Company and the preferred shareholder are in litigation regarding the number of votes currently held by that shareholder (See Note 11). As described above, during the year ended December 31, 2013, the Company issued the 5,000,000 shares of Series a Convertible Preferred Stock and the 10,000 of common stock described above in exchange for the $210,000 as payment towards outstanding principle of the debt. In addition, the Company issued 15,000,000 shares of Series A Convertible Preferred Stock as a penalty in settlement of the terms of the forbearance agreement. The fair value of the Preferred Stock of $274,050 was included in interest expense for the year ended December 31, 2013. On September 30, 2013, the Company issued 8,772 shares of its common stock as payment of $100,000 towards cash advances. On December 24, 2013, the Company issued 3,916 shares of its common stock as payment of accrued interest through June 30, 2013 of $85,447. On April 2, 2014, the Company issued 275 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2014 per the forbearance agreement. On September 17, 2014, limited waiver and forbearance agreement entered into on October 1, 2012 to provide that the perpetual license on products as described for resale, relicensing and commercialization outside the United States was amended as such to condition upon NorthStar providing certain financing, which financing the Company, in its sole discretion, could decline and retain the license. On October 3, 2014, the Company issued 515 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2014 per the forbearance agreement. On April 3, 2015, the Company issued 1,363 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2015 per the forbearance agreement. On October 2, 2015, the Company issued 4,156 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2015 per the forbearance agreement. On October 7, 2015, the Company issued 34,522 shares of its common stock in settlement of $100,000 principal payment towards the outstanding debt. On April 7, 2016, the Company issued 57,778 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due April 1, 2016 per the forbearance agreement. As of September 30, 2016 and December 31, 2015, the principal of this note was $262,000. Officer and Director Notes September 30, 2016 December 31, 2015 (audited) Note payable, Beverly Murphy 50,000 50,000 Note payable, Mr. Tomas 184,274 252,250 Note payable, Mr. Tomas 375,000 375,000 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 500,000 - Note payable, Ms. Comella 282,422 287,772 Note payable, Ms. Comella 300,000 - Total $ 2,191,696 $ 1,465,022 Note payable, Ms. Murphy At September 30, 2016 and December 31, 2015, the Company has outstanding promissory note payable of $50,000 due to Beverly Murphy with interest at 7% per annum due at maturity at October 15, 2015. Notes payable, Mr. Tomas In 2013, the Company issued a promissory note payable for previous advances and accrued compensation. The promissory note bears interest of 5% per annum and due on demand. During the nine months ended September 30, 2016, the Company paid off $67,976 of the outstanding promissory note. The principal outstanding balance of this note as of September 30, 2016 is $184,274. On August 1, 2013, the Company issued a $375,000 promissory note due on demand in settlement of accrued compensation. The promissory note bears interest of 5% per annum and is due on demand. The principal outstanding balance of this note as of September 30, 2016 is $375,000. On July 1, 2014, the Company issued a $500,000 promissory note in settlement of accrued compensation. The promissory note bears interest of 5% per annum and was due on January 1, 2015. The principal outstanding balance of this note as of September 30, 2016 is $500,000. On September 6, 2016, the Company issued a $500,000 promissory note in settlement of accrued compensation. The promissory note bears interest of 5% per annum and is due upon demand. The principal outstanding balance of this note as of September 30, 2016 is $500,000. Notes payable, Ms. Comella On July 1, 2014, the Company issued a $300,000 promissory note in settlement of accrued compensation. The promissory note bears interest of 5% per annum and due on January 1, 2015. To date, the Company has paid $17,578 on the outstanding promissory note. For the nine months ended September 30, 2016, the Company paid off an aggregate of $5,350 of the outstanding promissory note. The principal outstanding balance of this promissory note as of September 30, 2016 is $282,422. On September 6, 2016, the Company issued a $300,000 promissory note in settlement of accrued compensation. The promissory note bears interest of 5% per annum and was due upon demand. The principal outstanding balance of this note as of September 30, 2016 is $300,000. Transactions with Pavillion During the three and nine months ended September 30, 2016, the Company purchased $-0- of lab kits from Pavillion, Inc., a related party whose owner is related to an officer of the Company. During the three and nine months ended September 30, 2015, the Company purchased $80,504 and $172,298 lab kits, respectively. As of September 30, 2016 and December 31, 2015, the Company had $69,973 and $242,271, respectively, in accounts payable owed to Pavillion. On May 1, 2016, the Company entered into a consulting agreement with Pavillion. The agreement is for 12 months and renewable for 6 month periods. Compensation is at $250 per hour or, at the Company’s discretion, in shares of the Company’s common stock. For the three and nine months ended September 30, 2016, the Company has incurred $30,000 and $50,000 under the agreement, respectively.

NOTE 8 - DERIVATIVE LIABILITIES

NOTE 8 - DERIVATIVE LIABILITIES	9 Months Ended
	Sep. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 8 — DERIVATIVE LIABILITIES Reset warrants On October 1, 2012, in connection with the forbearance agreement with Northstar as discussed in Note 7, the Company issued an aggregate of 15,000 common stock purchase warrants to purchase the Company’s common stock with an exercise price of $14.00 per share for ten years with anti-dilutive (reset) provisions. The Company has identified embedded derivatives related to the issued warrants. These embedded derivatives included certain and anti-dilutive (reset) provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date and to fair value as of each subsequent reporting date. At September 30, 2016, the fair value of the reset provision related to the embedded derivative liability of $88 was determined using the Binomial Option Pricing model with the following assumptions: dividend yield: 0%; volatility: 216.11%; risk free rate: 1.14%; and expected life: 6.00 years. The Company recorded a gain on change in derivative liabilities of $103 and $12,120 during the three and nine months ended September 30, 2016. Convertible notes In fiscal 2015 and the nine months ended September 30, 2016, the Company issued convertible promissory notes. These promissory notes are convertible into common stock, at holders’ option, at a discount to the market price of the Company’s common stock. The Company has identified the embedded derivatives related to these promissory notes relating to certain anti-dilutive (reset) provisions. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of these notes and to fair value as of each subsequent reporting date. The fair value of the embedded derivatives at September 30, 2016, in the amount of $772,020, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 216.11%, (3) weighted average risk-free interest rate of 0.29% to 0.59%, (4) expected lives of 0.18 to 0.97 years, and (5) estimated fair value of the Company’s common stock of $0.007 per share. The Company recorded a loss on change in derivative liabilities of $413,320 and $281,942 during the three and nine months ended September 30, 2016. Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible promissory notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

NOTE 9 - STOCKHOLDERS' EQUITY

NOTE 9 - STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9 — STOCKHOLDERS’ EQUITY Common stock During the nine months ended September 30, 2016, the Company issued an aggregate of 26,060,886 shares of its common stock for the conversion of $404,831 of promissory notes payable and related accrued interest. Upon conversion of the notes, the Company recorded an adjustment to the derivative liability in the amount of $540,587 (see Note 12). During the nine months ended September 30, 2016, the Company purchased 10,250 shares of the Company’s common stock in the open market at an average cost of $0.76 per share. During the nine months ended September 30, 2016, the Company returned and canceled 95,461 shares of the Company’s common stock previously purchased (treasury shares) at an average cost of $2.41 per share.

NOTE 10 - STOCK OPTIONS AND WAR

NOTE 10 - STOCK OPTIONS AND WARRANTS	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 10 — STOCK OPTIONS AND WARRANTS Stock Options In December 1999, the Board of Directors and shareholders adopted the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the Plans. The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011. On April 1, 2013, the Board of Directors approved, subject to shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan reserves up to fifty thousand shares of common stock for issuance. On August 4, 2014, the Board of Directors approved to set the reserve to one hundred thousand shares of common stock for issuance and to close the 1999 Officers and Employees Stock Option Plan. On February 2, 2015, at the annual meeting of shareholders, the majority of shareholders approved the 2013 Omnibus Equity Compensation Plan. On November 2, 2015, the Board of Directors approved the increase of the reserve under the 2013 Omnibus Plan to five hundred million shares of common stock for issuance and effective September 16, 2016, approved an addition of twenty five million shares of common stock to the reserve. A summary of options at September 30, 2016 and activity during the nine months then ended is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Options outstanding at January 1, 2015 66,933 $ 56.00 8.9 Granted 489,116 $ 1.98 10.0 Exercised — Forfeited/Expired (229 ) $ 5,103.28 Options outstanding at December 31, 2015 555,820 $ 6.43 9.6 Granted 23,000,000 $ 0.02 10.0 Exercised — Forfeited/Expired (43 ) $ 1,960.39 Options outstanding at September 30, 2016 23,555,777 $ 0.03 9.9 Options exercisable at September 30, 2016 8,376,579 $ 0.06 9.9 Available for grant at September 30, 2016 9,383,070 The following information applies to options outstanding and exercisable at September 30, 2016: Exercise Number Option Outstanding Options Average Remaining Contractual Life (years) Weighted Average Number Options Exercisable Weighted Average Exercise price $ 0.0196 22,850,000 9.98 $ 0.0196 7,850,000 $ 0.0196 0.15402 705,412 9.01 0.15402 526,326 0.15402 19.32 150 8.10 19.32 38 19.32 70.00 100 4.92 70.00 100 70.00 210.00 40 4.87 210.00 40 210.00 680.00 40 3.36 680.00 40 680.00 5,250.00 35 1.55 5,250.00 35 5,250.00 Total 23,555,777 9.95 $ 0.3336 8,376,579 $ 0.05515 On April 18, 2016, the Company granted an aggregate 150,000 options to purchase the Company’s common stock at $0.15402 per share to key employees, vesting over 4 years, at grant date anniversary and exercisable over 10 years. The aggregate fair value of $10,928, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 184.48% and Risk free rate: 1.54%. On April 18, 2016, the Company repriced an aggregate of 555,433 previously issued options with exercise prices from $1.71 to $7,688.83 per share to $0.15402 per share. All other terms and conditions were unchanged. The aggregate change in fair value of $934, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 184.48% and Risk free rate: 0.22% to 1.78%, was charged to current period operations. On September 19, 2016, the Company granted an aggregate 22,850,000 options to purchase the Company’s common stock at $0.0196 per share to officers, directors and key employees with 15,000,000 vesting over 4 years, at grant date anniversary and 7,850,000 vesting immediately; for a term of 10 years. The aggregate fair value of $347,706, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 213.30% and Risk free rate: 1.22%. The fair value of all options vesting during the three and nine months ended September 30, 2016 of $188,009 and $329,814, respectively, was charged to current period operations. The fair value of all options vesting during the three and nine months ended September 30, 2015 of $73,520 and $345,761, respectively, was charged to current period operations. As of September 30, 2016, the Company had approximately $519,043 of total unrecognized compensation cost related to non-vested awards granted under the Plan, which the Company expects to recognize over a weighted average period of 1.37 years. Warrants A summary of common stock purchase warrants at September 30, 2016 and activity during the nine months ended September 30, 2016 is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Outstanding at January 1, 2015 150,620 $ 170.00 6.6 Issued 2,072 $ 19.98 8.18 Exercised - Expired (13,325 ) $ 24.00 Outstanding at December 31, 2015 139,367 $ 182.26 6.3 Issued - Exercised - Expired (222 ) $ 5,966.40 Outstanding at September 30, 2016 139,145 $ 173.03 5.5 Exercisable at September 30, 2016 135,600 $ 89.42 5.5 The following information applies to common stock purchase warrants outstanding and exercisable at September 30, 2016: Warrants Outstanding Warrants Exercisable Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.01 – $20.00 94,108 6.0 $ 15.54 94,108 $ 15.54 $ 20.01 – $30.00 29,743 5.3 $ 24.52 28,743 $ 24.62 $ 30.01 – $40.00 628 0.9 $ 40.00 628 $ 40.00 $ 40.01 - $50.00 6,253 2.4 $ 48.36 5,253 $ 48.41 $ 50.01 – $60.00 543 1.2 $ 60.00 543 $ 60.00 $ >60.00 7,870 3.5 $ 2,735.01 6,325 $ 1,524.67 139,145 5.5 $ 173.03 135,600 $ 89.42

NOTE 11 - COMMITMENTS AND CONTI

NOTE 11 - COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 11 — COMMITMENTS AND CONTINGENCIES Leases On February 4, 2016, the Company amended its facility lease to extend the term of the lease until August 31, 2019. Approximate annual future minimum lease obligations under non-cancelable operating lease agreements as of September 30, 2016 are as follows: Period ending December 31, 2016 (three months) $ 21,919 2017 87,674 2018 87,674 2019 58,448 Total $ 255,715 Litigation On September 17, 2015, a product liability lawsuit was filed in Broward County, specifically Patsy Bade v. Bioheart, Inc. US Stem Cell Clinics LLC, Aleiandro Perez, ARNP, and Shareen Greenbaum, M.D., and on November 30, 2015, a product liability lawsuit was filed in Broward County, specifically Elizabeth Noble v. Bioheart, Inc. US Stem Cell Clinics LLC, Aleiandro Perez, ARNP, and Shareen Greenbaum, M.D. During the nine months ended September 30, 2016, both matters settled by the Company’s insurance policy with no additional cost to the Company. On February 8, 2016, a collection lawsuit was filed in Broward County, specifically Roche Diagnostics Corp. v. U.S. Stem Cell, Inc., demanding judgement against the Company for an aggregate of $42,246 plus interest and costs for alleged unpaid product. During the nine months ended September 30, 2016, the Company settled all matters for a net payment of $8,500. On August 30 th On November 7, 2016, the Board of Directors, formed a separate committee to review and advise on improper activities undertaken by Charles Hart both during his tenure as a member of the Board of Directors and subsequent to his termination from the Board of Directors, specifically during the ninety days following his termination in which he is still considered an affiliate of the Company. (See the Current Report on Form 8-K, filed with the Securities and Exchange Committee on August 2, 2016, reporting that on August 1, 2016, Charles Hart was removed as a member of the Board of Directors). The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity. There was no outstanding litigation as of September 30, 2016 other then described above.

NOTE 12 - FAIR VALUE MEASUREMEN

NOTE 12 - FAIR VALUE MEASUREMENT	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 12 — FAIR VALUE MEASUREMENT The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements. The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity. As of September 30, 2016 or December 31, 2015, the Company did not have any items that would be classified as level 1 or 2 disclosures. The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in notes 6 and 8. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Notes 6 and 8 are that of volatility and market price of the underlying common stock of the Company. As of September 30, 2016 and December 31, 2015, the Company did not have any derivative instruments that were designated as hedges. The derivative liability as of September 30, 2016, in the amount of $772,108 has a level 3 classification. The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of September 30, 2016: Warrant Liability Debt Derivative Balance, December 31, 2014 149,920 $ 591,351 Total (gains) losses Initial fair value of debt derivative at note issuance — 1,097,379 Mark-to-market at December 31, 2015: (137,711 ) 122,616 Transfers out of Level 3 upon conversion and settlement of notes — (1,399,628 ) Balance, December 31, 2015 12,209 411,718 Total (gains) losses Initial fair value of debt derivative at note issuance — 618,946 Mark-to-market at September 30, 2016: (12,121 ) 281,943 Transfers out of Level 3 upon conversion or payoff of notes payable — (540,587 ) Balance, September 30, 2016 $ 88 $ 772,020 Net gain (loss) for the period included in earnings relating to the liabilities held at September 30, 2016 $ 12,121 $ (281,943 ) Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. The Company’s stock volatility increased approximately 21% from December 31, 2015 to September 30, 2016. As the stock volatility increases for each of the related derivative instruments, the value to the holder of the instrument generally increases. Stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments. The estimated fair value of these liabilities is sensitive to changes in the Company’s expected volatility. Increases in expected volatility would generally result in a higher fair value measurement.

NOTE 13 - SUBSEQUENT EVENTS

NOTE 13 - SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 13 — SUBSEQUENT EVENTS Subsequent common stock issuances In October and November 2016, the Company issued an aggregate of 29,511,799 and 848,490 shares of its common stock in settlement of $37,950 notes payable and six months interest totaling $12,705 on Northstar note payable. On August 30 th On November 7, 2016, the Board of Directors, formed a separate committee to review and advise on improper activities undertaken by Charles Hart both during his tenure as a member of the Board of Directors and subsequent to his termination from the Board of Directors, specifically during the ninety days following his termination in which he is still considered an affiliate of the Company. Charles Hart was a member of the Board of Directors of NorthStar and is, to our knowledge, is no longer a Director but remains a Member of the closely held NorthStar Biotech Group, LLC. (See the Current Report on Form 8-K, filed with the Securities and Exchange Committee on August 2, 2016, reporting that o n August 1, 2016, Charles Hart was removed as a member of the Board of Directors).

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis and business presentation U.S. Stem Cell, Inc. was incorporated under the laws of the State of Florida in August, 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine/cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. To date, the Company has not generated significant sales revenues in that they remain less than their total operating expenses, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a research and development business enterprise.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client. The Company’s primary sources of revenue are from the sale of test kits and equipment, training services, patient treatments and laboratory services, and cell banking. Revenues for kits and equipment sold are not recorded until kits and equipment are shipped. Revenues from trainings are recognized when the training occurs. Any cash received as a deposit for trainings are recorded by the company as a liability. Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for cell banking sales are accounted for as Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Because the Company sells its services separately, on more than a limited basis and at a price within a narrow range, the Company was able to allocate revenue based on vendor-specific objective evidence of fair value (VSOE). At September 30, 2016 and December 31, 2015, the Company had deferred revenues of $98,699 and $71,961, respectively.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Receivables, Policy [Policy Text Block]	Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of September 30, 2016 and December 31, 2015, allowance for doubtful accounts was $15,306 and $-0-, respectively.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.
Equity Method Investments, Policy [Policy Text Block]	Investments The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 33 percent ownership of U.S. Stem Cell Clinic, LLC utilizing the equity method of accounting. (See Note 3)
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock based compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of September 30, 2016, there were outstanding stock options to purchase 23,555,777 shares of common stock, 8,376,579 shares of which were vested.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period, adjusted to give effect to the 1,000-for-1 reverse stock split, which was effective in the market on November 5, 2015. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share for the three and nine months ended September 30, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2016 September 30, 2015 Convertible debt 147,287,847 371,441 Series A convertible preferred stock 20,000,000 20,000,000 Options to purchase common stock 23,555,777 73,804 Warrants to purchase common stock 139,145 138,739 Totals 190,982,769 20,583,984
Stockholders' Equity, Policy [Policy Text Block]	Treasury Stock The Company uses the cost method when it purchases its own common stock as treasury shares and displays treasury stock as a reduction of shareholders’ equity.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. As of September 30, 2016, five customers represented 22%, 18%, 13%, 10% and 10%, respectively, representing an aggregate of 73% of the Company’s accounts receivable. As of December 31, 2015, three customers represented 32%, 18% and 16% respectively, representing an aggregate of 66% of the Company’s accounts receivable. For the three months ended September 30, 2016, the Company’s revenues earned from the sale of products and services were $729,813, of which one customer represented 18% of the Company’s revenues. For the three months ended September 30, 2015, the Company’s revenues earned from the sale of products and services were $557,612, of which one customer represented 11% of the Company’s revenues. For the nine months ended September 30, 2016, the Company’s revenues earned from the sale of products and services were $2,097,341, of which one customer represented 13% of the Company’s revenues. For the nine months ended September 30, 2015, the Company’s revenues earned from the sale of products and services were $1,612,476, of which no customers represented 10% or more of the Company’s revenues.
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $1,847 and $9,313 for the three and nine months ended September 30, 2016, respectively; and $12,764 and $39,696 for the three and nine months ended September 30, 2015, respectively.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Derivatives, Policy [Policy Text Block]	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2016 and December 31, 2015, the Company did not have any derivative instruments that were designated as hedges. At September 30, 2016 and December 31, 2015, the Company had outstanding convertible notes and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 6 and Note 8)
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.
Reclassification, Policy [Policy Text Block]	Reclassification Certain reclassifications have been made to prior periods’ data to conform to the current year’s presentation. These reclassifications had no effect on reported income or losses.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.

NOTE 1 - SIGNIFICANT ACCOUNTI22

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2016 September 30, 2015 Convertible debt 147,287,847 371,441 Series A convertible preferred stock 20,000,000 20,000,000 Options to purchase common stock 23,555,777 73,804 Warrants to purchase common stock 139,145 138,739 Totals 190,982,769 20,583,984

NOTE 4 - PROPERTY AND EQUIPME23

NOTE 4 - PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of September 30, 2016 and December 31, 2015 is summarized as follows: September 30, 2016 December 31, 2015 (audited) Laboratory and medical equipment $ 342,218 $ 353,253 Furniture, fixtures and equipment 130,410 130,410 Computer equipment 48,788 48,788 Leasehold improvements 362,046 362,046 883,462 894,497 Less accumulated depreciation and amortization (860,635 ) (880,325 ) $ 22,827 $ 14,172

NOTE 5 - ACCRUED EXPENSES (Tabl

NOTE 5 - ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2016
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consisted of the following as of September 30, 2016 and December 31, 2015: September 30, 2016 December 31, 2015 (audited) Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest $ 131,506 $ 64,199 Interest payable on notes payable 563,174 467,664 Vendor accruals and other 146,429 147,244 Employee commissions, compensation, etc. 29,918 47,644 $ 871,027 $ 726,751

NOTE 6 - NOTES PAYABLE (Tables)

NOTE 6 - NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Promissory notes payable were comprised of the following as of September 30, 2016 and December 31, 2015: September 30, 2016 December 31, 2015 (audited) Seaside Bank note payable. $ 980,000 $ 980,000 Hunton & Williams notes payable 384,972 384,972 Daniel James Management notes payable 50,000 75,000 Fourth Man, LLC notes payable 100,000 77,450 Magna Group notes payable 179,240 125,000 Power Up Lending Group notes payable 241,650 194,235 Equipment finance lease 3,910 4,777 Total notes payable 1,939,772 1,841,434 Less unamortized debt discount (203,021 ) (249,205 ) Total notes payable net of unamortized debt discount 1,736,751 1,592,229 Less current portion (753,974 ) (608,502 ) Long term portion $ 982,777 $ 983,727

NOTE 7 - RELATED PARTY TRANSA26

NOTE 7 - RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	Officer and Director Notes September 30, 2016 December 31, 2015 (audited) Note payable, Beverly Murphy 50,000 50,000 Note payable, Mr. Tomas 184,274 252,250 Note payable, Mr. Tomas 375,000 375,000 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 500,000 - Note payable, Ms. Comella 282,422 287,772 Note payable, Ms. Comella 300,000 - Total $ 2,191,696 $ 1,465,022

NOTE 10 - STOCK OPTIONS AND W27

NOTE 10 - STOCK OPTIONS AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of options at September 30, 2016 and activity during the nine months then ended is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Options outstanding at January 1, 2015 66,933 $ 56.00 8.9 Granted 489,116 $ 1.98 10.0 Exercised — Forfeited/Expired (229 ) $ 5,103.28 Options outstanding at December 31, 2015 555,820 $ 6.43 9.6 Granted 23,000,000 $ 0.02 10.0 Exercised — Forfeited/Expired (43 ) $ 1,960.39 Options outstanding at September 30, 2016 23,555,777 $ 0.03 9.9 Options exercisable at September 30, 2016 8,376,579 $ 0.06 9.9 Available for grant at September 30, 2016 9,383,070
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following information applies to options outstanding and exercisable at September 30, 2016: Exercise Number Option Outstanding Options Average Remaining Contractual Life (years) Weighted Average Number Options Exercisable Weighted Average Exercise price $ 0.0196 22,850,000 9.98 $ 0.0196 7,850,000 $ 0.0196 0.15402 705,412 9.01 0.15402 526,326 0.15402 19.32 150 8.10 19.32 38 19.32 70.00 100 4.92 70.00 100 70.00 210.00 40 4.87 210.00 40 210.00 680.00 40 3.36 680.00 40 680.00 5,250.00 35 1.55 5,250.00 35 5,250.00 Total 23,555,777 9.95 $ 0.3336 8,376,579 $ 0.05515
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of common stock purchase warrants at September 30, 2016 and activity during the nine months ended September 30, 2016 is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Outstanding at January 1, 2015 150,620 $ 170.00 6.6 Issued 2,072 $ 19.98 8.18 Exercised - Expired (13,325 ) $ 24.00 Outstanding at December 31, 2015 139,367 $ 182.26 6.3 Issued - Exercised - Expired (222 ) $ 5,966.40 Outstanding at September 30, 2016 139,145 $ 173.03 5.5 Exercisable at September 30, 2016 135,600 $ 89.42 5.5
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following information applies to common stock purchase warrants outstanding and exercisable at September 30, 2016: Warrants Outstanding Warrants Exercisable Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.01 – $20.00 94,108 6.0 $ 15.54 94,108 $ 15.54 $ 20.01 – $30.00 29,743 5.3 $ 24.52 28,743 $ 24.62 $ 30.01 – $40.00 628 0.9 $ 40.00 628 $ 40.00 $ 40.01 - $50.00 6,253 2.4 $ 48.36 5,253 $ 48.41 $ 50.01 – $60.00 543 1.2 $ 60.00 543 $ 60.00 $ >60.00 7,870 3.5 $ 2,735.01 6,325 $ 1,524.67 139,145 5.5 $ 173.03 135,600 $ 89.42

NOTE 11 - COMMITMENTS AND CON28

NOTE 11 - COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	On February 4, 2016, the Company amended its facility lease to extend the term of the lease until August 31, 2019. Approximate annual future minimum lease obligations under non-cancelable operating lease agreements as of September 30, 2016 are as follows: Period ending December 31, 2016 (three months) $ 21,919 2017 87,674 2018 87,674 2019 58,448 Total $ 255,715

NOTE 12 - FAIR VALUE MEASUREM29

NOTE 12 - FAIR VALUE MEASUREMENT (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of September 30, 2016: Warrant Liability Debt Derivative Balance, December 31, 2014 149,920 $ 591,351 Total (gains) losses Initial fair value of debt derivative at note issuance — 1,097,379 Mark-to-market at December 31, 2015: (137,711 ) 122,616 Transfers out of Level 3 upon conversion and settlement of notes — (1,399,628 ) Balance, December 31, 2015 12,209 411,718 Total (gains) losses Initial fair value of debt derivative at note issuance — 618,946 Mark-to-market at September 30, 2016: (12,121 ) 281,943 Transfers out of Level 3 upon conversion or payoff of notes payable — (540,587 ) Balance, September 30, 2016 $ 88 $ 772,020 Net gain (loss) for the period included in earnings relating to the liabilities held at September 30, 2016 $ 12,121 $ (281,943 )

NOTE 1 - SIGNIFICANT ACCOUNTI30

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2013
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Deferred Revenue, Current (in Dollars)	$ 98,699		$ 98,699		$ 71,961
Allowance for Doubtful Accounts Receivable, Current (in Dollars)	$ 15,306		$ 15,306
Allowance for Doubtful Accounts Receivable (in Dollars)					$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)	23,555,777		23,555,777		555,820	66,933
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in Shares)	8,376,579		8,376,579
Revenue, Net (in Dollars)	$ 729,813	$ 557,612	$ 2,118,981	$ 1,612,476
Research and Development Expense (in Dollars)	$ 1,847	$ 12,764	9,313	$ 39,696
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Revenue, Net (in Dollars)			$ 2,097,341
Customer One [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage			22.00%		32.00%
Customer Two [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage			18.00%		18.00%
Customer Three [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage			13.00%		16.00%
Customer Four [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage			10.00%
Customer Five [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage			10.00%
Five Major Customers [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage			73.00%
Three Major Customers [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage					66.00%
A Single Customer [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage	18.00%	11.00%	13.00%
U.S. Stem Cell Clinic, LLC [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	33.00%		33.00%

NOTE 1 - SIGNIFICANT ACCOUNTI31

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	190,982,769	20,583,984
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	147,287,847	371,441
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	23,555,777	73,804
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	139,145	138,739
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	20,000,000	20,000,000

NOTE 2 - GOING CONCERN AND MA32

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income (Loss) Attributable to Parent	$ (1,680,405)	$ (121,359)	$ (2,396,635)	$ (282,982)
Net Cash Provided by (Used in) Operating Activities			$ (113,432)	$ (789,462)

NOTE 3 - INVESTMENTS (Details)

NOTE 3 - INVESTMENTS (Details) - USD ($)	3 Months Ended		9 Months Ended		24 Months Ended	206 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Sep. 30, 2016
NOTE 3 - INVESTMENTS (Details) [Line Items]
Payments for (Proceeds from) Investments			$ (115,000)	$ 10,000
Income (Loss) from Equity Method Investments	$ 54,729	$ 11,625	85,927	23,934		$ 115,352
Investments	$ 60,066		$ 60,066		$ 89,139	$ 60,066
U.S. Stem Cell Clinic, LLC [Member]
NOTE 3 - INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage	33.00%		33.00%			33.00%
Payments for (Proceeds from) Investments					59,714
Income (Loss) from Equity Method Investments	$ 54,729	11,625	$ 85,927	23,934
Proceeds from Equity Method Investment, Dividends or Distributions			115,000
Investments	60,066		60,066			$ 60,066
Accounts Receivable, Net	9,280		9,280		$ 5,946	$ 9,280
Revenues	$ 142,774	$ 63,989	$ 303,625	$ 124,484

NOTE 4 - PROPERTY AND EQUIPME34

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Gain (Loss) on Disposition of Property Plant Equipment	$ 0	$ 0	$ 500	$ 0

NOTE 4 - PROPERTY AND EQUIPME35

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property and Equipment - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Schedule of Property and Equipment [Abstract]
Laboratory and medical equipment	$ 342,218	$ 353,253
Furniture, fixtures and equipment	130,410	130,410
Computer equipment	48,788	48,788
Leasehold improvements	362,046	362,046
	883,462	894,497
Less accumulated depreciation and amortization	(860,635)	(880,325)
	$ 22,827	$ 14,172

NOTE 5 - ACCRUED EXPENSES (Deta

NOTE 5 - ACCRUED EXPENSES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Gain (Loss) on Extinguishment of Debt	$ (23,133)	$ 58,873	$ 49,681	$ 2,097,483
Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			1,419,675
Common Stock Issued in Settlement of Guarantor Fees [Member]
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Gain (Loss) on Extinguishment of Debt			$ 134,967

NOTE 5 - ACCRUED EXPENSES (De37

NOTE 5 - ACCRUED EXPENSES (Details) - Schedule of Accrued Liabilities - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Schedule of Accrued Liabilities [Abstract]
Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest	$ 131,506	$ 64,199
Interest payable on notes payable	563,174	467,664
Vendor accruals and other	146,429	147,244
Employee commissions, compensation, etc.	29,918	47,644
	$ 871,027	$ 726,751

NOTE 6 - NOTES PAYABLE (Details

NOTE 6 - NOTES PAYABLE (Details)	Aug. 16, 2016USD ($)	Mar. 23, 2016USD ($)	Dec. 03, 2015USD ($)	Jun. 01, 2015USD ($)	Sep. 30, 2016USD ($)$ / shares	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)$ / shares	Sep. 30, 2015USD ($)	Dec. 31, 2015USD ($)	Jul. 31, 2015USD ($)	Dec. 12, 2014USD ($)shares	Oct. 25, 2010USD ($)
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Notes Payable					$ 1,939,772		$ 1,939,772		$ 1,841,434
Derivative Liability, Current					772,108		772,108		423,927
Gain (Loss) on Extinguishment of Debt					(23,133)	$ 58,873	49,681	$ 2,097,483
Amortization of Debt Discount (Premium)							556,910	612,811
Repayments of Notes Payable							$ 228,814	$ 143,818
Embedded Derivative Financial Instruments [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Fair Value Assumptions, Expected Dividend Rate							0.00%
Fair Value Assumptions, Expected Volatility Rate							216.11%
Fair Value Assumptions, Risk Free Interest Rate							1.14%
Fair Value Assumptions, Expected Term							6 years
Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Fair Value Assumptions, Expected Dividend Rate							0.00%
Fair Value Assumptions, Expected Volatility Rate							216.11%
Minimum [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate							0.29%
Fair Value Assumptions, Expected Term							65 days
Maximum [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate							0.59%
Fair Value Assumptions, Expected Term							354 days
Seaside National Bank and Trust [Member] | Notes Payable to Banks [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount												$ 980,000
Debt Instrument, Interest Rate, Stated Percentage												4.25%
Debt Instrument, Maturity Date							Jan. 11, 2018
Notes Payable					$ 980,000		$ 980,000		$ 980,000
Hunton & Williams Notes [Member] | Notes Payable, Other Payables [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					8.00%		8.00%		8.00%
Number of Outstanding Notes Payable					2		2		2
Notes Payable					$ 384,972		$ 384,972		$ 384,972
Debt Instrument, Payment Terms							payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.		payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.
Hunton & Williams Note #1 [Member] | Notes Payable, Other Payables [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Notes Payable					61,150		$ 61,150		$ 61,150
Hunton & Williams Note #2 [Member] | Notes Payable, Other Payables [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Notes Payable					323,822		323,822		323,822
Daniel James Management Notes Payable [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount					$ 75,000		$ 75,000
Debt Instrument, Interest Rate, Stated Percentage					9.50%		9.50%
Debt Instrument, Maturity Date							Mar. 9, 2017
Notes Payable					$ 50,000		$ 50,000		75,000
Debt Instrument, Term							1 year
Debt Instrument, Convertible, Terms of Conversion Feature							convertible into common stock, at holder’s option, at a 47% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion
Daniel James Management Notes Payable [Member] | Conversion of Note and Interest Outstanding at December 31, 2016 [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount							$ 75,000
Daniel James Management Notes Payable [Member] | Conversion of Note and Interest Issued in Current Period [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount							25,000
Daniel James Management Notes Payable [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Derivative Liability, Current					126,304		126,304
Embedded Derivative, Fair Value of Embedded Derivative Liability					139,691		139,691
Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount					$ 100,000		$ 100,000
Debt Instrument, Interest Rate, Stated Percentage					9.50%		9.50%
Notes Payable					$ 100,000		$ 100,000		77,450
Debt Instrument, Term							1 year
Debt Instrument, Convertible, Terms of Conversion Feature							convertible into common stock, at holder’s option, at a 49% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion
Derivative Liability, Current					286,415		$ 286,415
Embedded Derivative, Fair Value of Embedded Derivative Liability					216,050		216,050
Debt Conversion, Original Debt, Amount							77,450
Magna Group Notes Payable [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount			$ 262,500
Debt Instrument, Interest Rate, Stated Percentage			12.00%
Notes Payable					179,240		179,240		125,000
Debt Instrument, Payment Terms			In the event the Company prepays the Note in full, the Company is required to pay off all principal at 140%, interest and any other amounts.
Debt Instrument, Convertible, Terms of Conversion Feature			convertible into common stock, at Magna’s option, at the lower of I) 40% discount to the lowest sales price of the common stock during the 5 trading day period prior to conversion or ii) $0.70.
Debt Conversion, Original Debt, Amount							208,260
Proceeds from Convertible Debt			$ 250,000
Debt Instrument, Original Issue Discount, Percentage			5.00%
Debt Instrument, Unamortized Discount			$ 12,500
Debt Instrument, Number of Shares Authorized to be Converted (in Shares) | shares											341,718
Magna Group Notes Payable [Member] | Note Payable #1 [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount											$ 110,000
Magna Group Notes Payable [Member] | Note Payable #2 [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount											$ 262,500
Magna Group Notes Payable [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Derivative Liability, Current					359,301		359,301
Embedded Derivative, Fair Value of Embedded Derivative Liability					263,204		263,204
Power Up Lending Group Notes Payable [Member] | Revenue Based Factoring Agreement [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount	$ 283,500	$ 276,000
Notes Payable					241,650		241,650
Debt Instrument, Payment Terms	Under the terms of the agreement, the Company is required to make daily payments equal to $1,350 for 210 business days.	Under the terms of the agreement, the Company is required to make daily payments equal to $1,314 for 210 business days.
Debt Instrument, Unamortized Discount					64,725		64,725
Proceeds from Issuance of Debt	$ 210,000	$ 200,000
Debt Instrument, Fee Amount	2,000	1,650
Net Proceeds from Issuance of Debt	65,193	82,896
Gain (Loss) on Extinguishment of Debt	$ (49,264)	$ (39,449)
Interest Expense, Debt							10,775
Power Up Lending Group Notes Payable [Member] | Notes Payable, Other Payables [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Notes Payable					241,650		241,650		$ 194,235
Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Notes Payable, Other Payables [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount				$ 1,697,762
Debt Instrument, Maturity Date				Jun. 1, 2020
Notes Payable					1,547,762		1,547,762
Debt Instrument, Unamortized Discount					259,719		259,719			$ 368,615
Debt Instrument, Frequency of Periodic Payment				four semi-annual
Debt Instrument, Periodic Payment				$ 75,000
Debt Instrument, Date of First Required Payment				Dec. 31, 2015
Debt Instrument, Imputed Interest, Stated Percentage										5.00%
Amortization of Debt Discount (Premium)					19,506		59,666
Repayments of Notes Payable							75,000
Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Principal [Member] | Notes Payable, Other Payables [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Extinguishment of Debt, Amount				$ 1,500,000
Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Interest [Member] | Notes Payable, Other Payables [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Extinguishment of Debt, Amount				373,469
Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Guarantor Fees [Member] | Notes Payable, Other Payables [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Extinguishment of Debt, Amount				$ 624,737
Daniel, Fourth Man and Magna Notes [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability					772,020		772,020
Proceeds from Convertible Debt							425,000
Debt Instrument, Unamortized Discount					618,946		618,946
Interest Expense, Debt							193,946
Amortization of Debt Discount (Premium)					$ 138,721		$ 497,244
Fair Value Assumptions, Expected Dividend Rate							0.00%
Daniel, Fourth Man and Magna Notes [Member] | Minimum [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Fair Value Assumptions, Expected Volatility Rate							178.42%
Fair Value Assumptions, Risk Free Interest Rate							0.45%
Fair Value Assumptions, Expected Term							288 days
Share Price (in Dollars per share) | $ / shares					$ 0.0145		$ 0.0145
Daniel, Fourth Man and Magna Notes [Member] | Maximum [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) [Line Items]
Fair Value Assumptions, Expected Volatility Rate							213.94%
Fair Value Assumptions, Risk Free Interest Rate							0.69%
Fair Value Assumptions, Expected Term							1 year
Share Price (in Dollars per share) | $ / shares					$ 0.9342		$ 0.9342

NOTE 6 - NOTES PAYABLE (Detail

NOTE 6 - NOTES PAYABLE (Details) - Schedule of Notes Payable - USD ($)	Sep. 30, 2016	Dec. 31, 2015
NOTE 6 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	$ 1,939,772	$ 1,841,434
Less unamortized debt discount	(203,021)	(249,205)
Total notes payable net of unamortized debt discount	1,736,751	1,592,229
Less current portion	(753,974)	(608,502)
Long term portion	982,777	983,727
Capital Lease Obligations [Member]
NOTE 6 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	3,910	4,777
Seaside National Bank and Trust [Member] | Notes Payable to Banks [Member]
NOTE 6 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	980,000	980,000
Hunton & Williams Notes [Member] | Notes Payable, Other Payables [Member]
NOTE 6 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	384,972	384,972
Daniel James Management Notes Payable [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	50,000	75,000
Fourth Man, LLC Notes Payable [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	100,000	77,450
Magna Group Notes Payable [Member] | Convertible Debt [Member]
NOTE 6 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	179,240	125,000
Power Up Lending Group Notes Payable [Member] | Notes Payable, Other Payables [Member]
NOTE 6 - NOTES PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	$ 241,650	$ 194,235

NOTE 7 - RELATED PARTY TRANSA40

NOTE 7 - RELATED PARTY TRANSACTIONS (Details) - USD ($)	May 01, 2016	Apr. 07, 2016	Feb. 12, 2016	Oct. 07, 2015	Oct. 02, 2015	Apr. 03, 2015	Oct. 03, 2014	Jul. 01, 2014	Apr. 02, 2014	Dec. 24, 2013	Sep. 30, 2013	Oct. 01, 2012	Sep. 21, 2012	Mar. 30, 2012	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2013	Sep. 30, 2016	Sep. 16, 2016	Aug. 01, 2013	Feb. 28, 2013	Dec. 31, 2012	Feb. 29, 2012
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due to Related Parties, Current															$ 104,901		$ 104,901		$ 106,505		$ 104,901
Gain (Loss) on Extinguishment of Debt															$ (23,133)	$ 58,873	$ 49,681	$ 2,097,483
Class of Warrant or Rights, Granted (in Shares)																	0		2,072
Preferred Stock, Shares Authorized (in Shares)															20,000,000		20,000,000		20,000,000		20,000,000
Notes Payable, Related Parties															$ 2,191,696		$ 2,191,696		$ 1,465,022		$ 2,191,696
Repayments of Related Party Debt																	103,326	$ 0
Accounts Payable, Related Parties, Current															93,932		93,932		104,089		93,932
Series A Preferred Stock [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Preferred Stock, Shares Authorized (in Shares)																									20,000,000
Preferred Stock, Voting Rights												modify the voting rights of the Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock
Officers and Directors [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due to Related Parties, Current															104,901		104,901		106,505		104,901
Affiliated Entity [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Costs and Expenses, Related Party															80,504		172,298
Accounts Payable, Related Parties, Current															69,973		69,973		242,271		69,973
Related Party Transaction, Description of Transaction	The agreement is for 12 months and renewable for 6 month periods. Compensation is at $250 per hour or, at the Company’s discretion, in shares of the Company’s common stock
Related Party Transaction, Amounts of Transaction															30,000		50,000
Notes Payable, Other Payables [Member] | Affiliated Entity [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)										3,916	8,772									10,000
Debt Instrument, Face Amount																										$ 544,267
Debt Instrument, Payment Terms												Company is obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012).		agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.
Class of Warrant or Rights, Granted (in Shares)												15,000	5,000
Debt Instrument, Debt Default, Description of Violation or Event of Default												entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.
PercentageOfRevenuesToBeReceivedAsRoyalty												8.00%
Debt Instrument, Interest Rate, Stated Percentage												12.85%												7.00%
Debt Conversion, Converted Instrument, Amount										$ 85,447	$ 100,000									$ 210,000
Notes Payable, Related Parties															262,000		262,000		262,000		262,000
Notes Payable, Other Payables [Member] | Affiliated Entity [Member] | Series A Preferred Stock [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)																				5,000,000
Stock Issued During Period, Value, Other																				$ 274,050
Notes Payable, Other Payables [Member] | Affiliated Entity [Member] | Series A Preferred Stock [Member] | Settlement of Forbearance Agreement, Penalty [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)																				15,000,000
Notes Payable, Other Payables [Member] | Director [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Notes Payable, Related Parties															$ 50,000		$ 50,000		50,000		$ 50,000
Settlement of Related Party Advances [Member] | Officers and Directors [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)			14,606
Debt Conversion, Original Debt, Amount			$ 10,000
Gain (Loss) on Extinguishment of Debt			$ 3,427
Interest [Member] | Notes Payable, Other Payables [Member] | Affiliated Entity [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)		57,778			4,156	1,363	515		275
Debt Conversion, Converted Instrument, Amount		$ 12,705			$ 12,705	$ 12,635	$ 12,705		$ 12,635
Principal [Member] | Notes Payable, Other Payables [Member] | Affiliated Entity [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)				34,522
Debt Conversion, Original Debt, Amount				$ 100,000
Note Payable #1 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage															5.00%		5.00%				5.00%
Notes Payable, Related Parties															$ 184,274		$ 184,274		252,250		$ 184,274
Repayments of Related Party Debt																	67,976
Note Payable #1 [Member] | Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount								$ 300,000
Debt Instrument, Interest Rate, Stated Percentage								5.00%
Notes Payable, Related Parties															282,422		282,422		287,772		282,422
Repayments of Related Party Debt																	5,350				17,578
Debt Instrument, Maturity Date								Jan. 1, 2015
Note Payable #1 [Member] | Subordinated Debt [Member] | Director [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Notes Payable, Related Parties															50,000		50,000		50,000		50,000
Note Payable #2 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																							$ 375,000
Debt Instrument, Interest Rate, Stated Percentage																							5.00%
Notes Payable, Related Parties															375,000		375,000		375,000		375,000
Note Payable #2 [Member] | Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																						$ 300,000
Debt Instrument, Interest Rate, Stated Percentage																						5.00%
Notes Payable, Related Parties															$ 300,000		$ 300,000		$ 0		$ 300,000
Note Payable #2 [Member] | Subordinated Debt [Member] | Director [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage															7.00%		7.00%		7.00%		7.00%
Note Payable #3 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount								$ 500,000
Debt Instrument, Interest Rate, Stated Percentage								5.00%
Notes Payable, Related Parties															$ 500,000		$ 500,000		$ 500,000		$ 500,000
Debt Instrument, Maturity Date								Jan. 1, 2015
Note Payable #4 [Member] | Notes Payable, Other Payables [Member] | Chief Executive Officer [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																						$ 500,000
Debt Instrument, Interest Rate, Stated Percentage																						5.00%
Notes Payable, Related Parties															$ 500,000		$ 500,000		$ 0		$ 500,000

NOTE 7 - RELATED PARTY TRANSA41

NOTE 7 - RELATED PARTY TRANSACTIONS (Details) - Schedule of Related Party Notes Payable - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Notes Payable, Related Party	$ 2,191,696	$ 1,465,022
Director [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	50,000	50,000
Note Payable #1 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	184,274	252,250
Note Payable #1 [Member] | Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	282,422	287,772
Note Payable #2 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	375,000	375,000
Note Payable #2 [Member] | Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	300,000	0
Note Payable #3 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	500,000	500,000
Note Payable #4 [Member] | Chief Executive Officer [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	$ 500,000	$ 0

NOTE 8 - DERIVATIVE LIABILITI42

NOTE 8 - DERIVATIVE LIABILITIES (Details) - USD ($)	Oct. 01, 2012	Sep. 21, 2012	Sep. 30, 2016	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
NOTE 8 - DERIVATIVE LIABILITIES (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)				0	2,072
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 173.03	$ 173.03	$ 182.26	$ 170
Embedded Derivative Financial Instruments [Member]
NOTE 8 - DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative, Net (in Dollars)			$ 88	$ 88
Fair Value Assumptions, Expected Dividend Rate				0.00%
Fair Value Assumptions, Expected Volatility Rate				216.11%
Fair Value Assumptions, Risk Free Interest Rate				1.14%
Fair Value Assumptions, Expected Term				6 years
Derivative, Gain (Loss) on Derivative, Net (in Dollars)			103	$ 12,120
Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]
NOTE 8 - DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative, Net (in Dollars)			772,020	$ 772,020
Fair Value Assumptions, Expected Dividend Rate				0.00%
Fair Value Assumptions, Expected Volatility Rate				216.11%
Derivative, Gain (Loss) on Derivative, Net (in Dollars)			$ 413,320	$ 281,942
Fair Value of Common Stock (in Dollars per share)				$ 0.007
Affiliated Entity [Member] | Notes Payable, Other Payables [Member]
NOTE 8 - DERIVATIVE LIABILITIES (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)	15,000	5,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 14
Warrants, Term of Warrants	10 years
Minimum [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]
NOTE 8 - DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate				0.29%
Fair Value Assumptions, Expected Term				65 days
Maximum [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]
NOTE 8 - DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate				0.59%
Fair Value Assumptions, Expected Term				354 days

NOTE 9 - STOCKHOLDERS' EQUITY (

NOTE 9 - STOCKHOLDERS' EQUITY (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Common Stock [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Stock Repurchased During Period, Shares	10,250
Treasury Stock Acquired, Average Cost Per Share (in Dollars per share)	$ 0.76
Common Stock [Member] | Treasury Shares Retired [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Treasury Stock Acquired, Average Cost Per Share (in Dollars per share)	$ 2.41
Treasury Stock, Shares, Retired	95,461
Common Stock Issued in Settlement of Notes Payable and Accrued Interest [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	26,060,886
Debt Conversion, Original Debt, Amount (in Dollars)	$ 404,831
Fair Value, Inputs, Level 3 [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers out of Level 3 (in Dollars)	$ (540,587)	$ (1,399,628)

NOTE 10 - STOCK OPTIONS AND W44

NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - USD ($)	Sep. 16, 2016	Apr. 18, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Nov. 02, 2015	Aug. 04, 2014	Apr. 01, 2013
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	22,850,000	150,000			23,000,000		489,116
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)	$ 0.0196	$ 0.15402			$ 0.02		$ 1.98
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years	10 years
Sharebased Compensation Arrangement by Sharebased Payment Award Options, Fair Value (in Dollars)	$ 347,706	$ 10,928
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	213.30%	184.48%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.22%	1.54%
Other Noncash Expense (in Dollars)					$ 934	$ 0
Allocated Share-based Compensation Expense (in Dollars)			$ 188,009	$ 73,520	329,814	$ 345,761
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)			$ 519,043		$ 519,043
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					1 year 135 days
Options Modified [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Sharebased Compensation Arrangement by Sharebased Payment Award Options, Fair Value (in Dollars)		$ 0.15402
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		184.48%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Modified, Number (in Shares)		555,433
Other Noncash Expense (in Dollars)		$ 934
Bioheart 2013 Omnibus Equity Compensation Plan [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)								500,000,000	100,000	50,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in Shares)	25,000,000
Share-based Compensation Award, Tranche Two [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	15,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Award, Tranche One [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	7,850,000
Minimum [Member] | Options Modified [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		0.22%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Exercise Price (in Dollars per share)		$ 1.71
Maximum [Member] | Options Modified [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.78%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Exercise Price (in Dollars per share)		$ 7,688.83

NOTE 10 - STOCK OPTIONS AND W45

NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Option Activity - $ / shares	Sep. 16, 2016	Apr. 18, 2016	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule of Option Activity [Abstract]
Options Outstanding			555,820		66,933
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)			$ 6.43		$ 56
Options Outstanding, Weighted-Average Remaining Contractual Term			9 years 328 days	9 years 219 days	8 years 328 days
Options exercisable at September 30, 2016			8,376,579
Options exercisable at September 30, 2016 (in Dollars per share)			$ 0.06
Options exercisable at September 30, 2016			9 years 328 days
Available for grant at September 30, 2016			9,383,070
Options Granted	22,850,000	150,000	23,000,000	489,116
Options Granted, Weighted-Average Exercise Price (in Dollars per share)	$ 0.0196	$ 0.15402	$ 0.02	$ 1.98
Options Granted, Weighted-Average Remaining Contractual Term			10 years	10 years
Options Exercised			0	0
Options Forfeited/Expired			(43)	(229)
Options Forfeited/Expired, Weighted-Average Exercise Price (in Dollars per share)			$ 1,960.39	$ 5,103.28
Options Outstanding			23,555,777	555,820
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)			$ 0.03	$ 6.43

NOTE 10 - STOCK OPTIONS AND W46

NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Options Outstanding and Exercisable by Exercise Price Range	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Shares (in Shares) | shares	23,555,777
Options Outstanding, Weighted Average Remaining Contractual Term	9 years 346 days
Options Outstanding, Weighted Average Execise Price	$ 0.3336
Options Exercisable, Shares (in Shares) | shares	8,376,579
Options Exercisable, Weighted Average Execise Price	$ 0.05515
Options, $0.0196 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	$ 0.0196
Options Outstanding, Shares (in Shares) | shares	22,850,000
Options Outstanding, Weighted Average Remaining Contractual Term	9 years 357 days
Options Outstanding, Weighted Average Execise Price	$ 0.0196
Options Exercisable, Shares (in Shares) | shares	7,850,000
Options Exercisable, Weighted Average Execise Price	$ 0.0196
Options, $0.15402 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	$ 0.15402
Options Outstanding, Shares (in Shares) | shares	705,412
Options Outstanding, Weighted Average Remaining Contractual Term	9 years 3 days
Options Outstanding, Weighted Average Execise Price	$ 0.15402
Options Exercisable, Shares (in Shares) | shares	526,326
Options Exercisable, Weighted Average Execise Price	$ 0.15402
Options, $19.32 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	$ 19.32
Options Outstanding, Shares (in Shares) | shares	150
Options Outstanding, Weighted Average Remaining Contractual Term	8 years 36 days
Options Outstanding, Weighted Average Execise Price	$ 19.32
Options Exercisable, Shares (in Shares) | shares	38
Options Exercisable, Weighted Average Execise Price	$ 19.32
Options, $70.00 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	$ 70
Options Outstanding, Shares (in Shares) | shares	100
Options Outstanding, Weighted Average Remaining Contractual Term	4 years 335 days
Options Outstanding, Weighted Average Execise Price	$ 70
Options Exercisable, Shares (in Shares) | shares	100
Options Exercisable, Weighted Average Execise Price	$ 70
Options, $210.00 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	$ 210
Options Outstanding, Shares (in Shares) | shares	40
Options Outstanding, Weighted Average Remaining Contractual Term	4 years 317 days
Options Outstanding, Weighted Average Execise Price	$ 210
Options Exercisable, Shares (in Shares) | shares	40
Options Exercisable, Weighted Average Execise Price	$ 210
Options, $680.00 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	$ 680
Options Outstanding, Shares (in Shares) | shares	40
Options Outstanding, Weighted Average Remaining Contractual Term	3 years 131 days
Options Outstanding, Weighted Average Execise Price	$ 680
Options Exercisable, Shares (in Shares) | shares	40
Options Exercisable, Weighted Average Execise Price	$ 680
Options, $5,250.00 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price	$ 5,250
Options Outstanding, Shares (in Shares) | shares	35
Options Outstanding, Weighted Average Remaining Contractual Term	1 year 200 days
Options Outstanding, Weighted Average Execise Price	$ 5,250
Options Exercisable, Shares (in Shares) | shares	35
Options Exercisable, Weighted Average Execise Price	$ 5,250

NOTE 10 - STOCK OPTIONS AND W47

NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Activity - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule of Warrants Activity [Abstract]
Warrants Outstanding	139,145	139,367	150,620
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 173.03	$ 182.26	$ 170
Warrants Outstanding, Weighted-Average Remaining Contractual Term	5 years 6 months	6 years 109 days	6 years 219 days
Exercisable at September 30, 2016	135,600
Exercisable at September 30, 2016 (in Dollars per share)	$ 89.42
Exercisable at September 30, 2016	5 years 6 months
Warrants Issued	0	2,072
Warrants Issued, Weighted-Average Exercise Price (in Dollars per share)		$ 19.98
Warrants Issued, Weighted-Average Remaining Contractual Term		8 years 65 days
Warrants Exercised	0	0
Warrants Expired	(222)	(13,325)
Warrants Expired, Weighted-Average Exercise Price (in Dollars per share)	$ 5,966.40	$ 24

NOTE 10 - STOCK OPTIONS AND W48

NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	$ 173.03	$ 182.26	$ 170
Warrants Outstanding (in Shares)	139,145	139,367	150,620
Warrants Outstanding, Weighted-Average Remaining Contractual Term	5 years 6 months	6 years 109 days	6 years 219 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 173.03
Warrants Exercisable (in Shares)	135,600
Warrants Exercisable, Weighted-Average Exercise Price	$ 89.42
Class of Warrants or Rights, Exercise Price Range, $0.01-$20.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding (in Shares)	94,108
Warrants Outstanding, Weighted-Average Remaining Contractual Term	6 years
Warrants Outstanding, Weighted-Average Exercise Price	$ 15.54
Warrants Exercisable (in Shares)	94,108
Warrants Exercisable, Weighted-Average Exercise Price	$ 15.54
Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding (in Shares)	29,743
Warrants Outstanding, Weighted-Average Remaining Contractual Term	5 years 109 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 24.52
Warrants Exercisable (in Shares)	28,743
Warrants Exercisable, Weighted-Average Exercise Price	$ 24.62
Class of Warrants or Rights, Exercise Price Range, $30.01-$40.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding (in Shares)	628
Warrants Outstanding, Weighted-Average Remaining Contractual Term	328 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 40
Warrants Exercisable (in Shares)	628
Warrants Exercisable, Weighted-Average Exercise Price	$ 40
Class of Warrants or Rights, Exercise Price Range, $40.01-$50.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding (in Shares)	6,253
Warrants Outstanding, Weighted-Average Remaining Contractual Term	2 years 146 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 48.36
Warrants Exercisable (in Shares)	5,253
Warrants Exercisable, Weighted-Average Exercise Price	$ 48.41
Class of Warrants or Rights, Exercise Price Range, $50.01-$60.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding (in Shares)	543
Warrants Outstanding, Weighted-Average Remaining Contractual Term	1 year 73 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 60
Warrants Exercisable (in Shares)	543
Warrants Exercisable, Weighted-Average Exercise Price	$ 60
Class of Warrants or Rights, Exercise Price Range, Greater than $60.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding (in Shares)	7,870
Warrants Outstanding, Weighted-Average Remaining Contractual Term	3 years 6 months
Warrants Outstanding, Weighted-Average Exercise Price	$ 2,735.01
Warrants Exercisable (in Shares)	6,325
Warrants Exercisable, Weighted-Average Exercise Price	$ 1,524.67
Minimum [Member] | Class of Warrants or Rights, Exercise Price Range, $0.01-$20.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	0.01
Minimum [Member] | Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	20.01
Minimum [Member] | Class of Warrants or Rights, Exercise Price Range, $30.01-$40.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	30.01
Minimum [Member] | Class of Warrants or Rights, Exercise Price Range, $40.01-$50.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	40.01
Minimum [Member] | Class of Warrants or Rights, Exercise Price Range, $50.01-$60.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	50.01
Minimum [Member] | Class of Warrants or Rights, Exercise Price Range, Greater than $60.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	60
Maximum [Member] | Class of Warrants or Rights, Exercise Price Range, $0.01-$20.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	20
Maximum [Member] | Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	30
Maximum [Member] | Class of Warrants or Rights, Exercise Price Range, $30.01-$40.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	40
Maximum [Member] | Class of Warrants or Rights, Exercise Price Range, $40.01-$50.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	50
Maximum [Member] | Class of Warrants or Rights, Exercise Price Range, $50.01-$60.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	$ 60

NOTE 11 - COMMITMENTS AND CON49

NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Feb. 08, 2016	Sep. 30, 2016
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Loss Contingency, Damages Sought, Value	$ 42,246
Payments for Legal Settlements		$ 8,500
Northstar Claims [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Loss Contingency, Damages Sought		Northstar is seeking a declaratory judgment from the Court as to whether its preferred shares were the subject of the Company’s reverse stock split effective November 4, 2015 and also seeks the appointment of a receiver. Northstar did not seek money damages.

NOTE 11 - COMMITMENTS AND CON50

NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) - Schedule of Future Minimum Rental Payments for Operating Leases	Sep. 30, 2016USD ($)
Schedule of Future Minimum Rental Payments for Operating Leases [Abstract]
2016 (three months)	$ 21,919
2,017	87,674
2,018	87,674
2,019	58,448
Total	$ 255,715

NOTE 12 - FAIR VALUE MEASUREM51

NOTE 12 - FAIR VALUE MEASUREMENT (Details)	9 Months Ended
	Sep. 30, 2016USD ($)
Fair Value Disclosures [Abstract]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	$ 772,108
Percentage of Stock Price Decrease	(21.00%)

NOTE 12 - FAIR VALUE MEASUREM52

NOTE 12 - FAIR VALUE MEASUREMENT (Details) - Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Total (gains) losses
Balance	$ 772,108
Fair Value, Inputs, Level 3 [Member] | Embedded Derivative Financial Instruments [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	12,209	$ 149,920
Net gain (loss) for the period included in earnings relating to the liabilities held at September 30, 2016	12,121
Total (gains) losses
Mark-to-market	(12,121)	(137,711)
Balance	88	12,209
Fair Value, Inputs, Level 3 [Member] | Embedded Derivative Financial Instruments [Member] | Convertible Debt [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	411,718	591,351
Net gain (loss) for the period included in earnings relating to the liabilities held at September 30, 2016	(281,943)
Total (gains) losses
Initial fair value of derivative	618,946	1,097,379
Mark-to-market	281,943	122,616
Transfers out of Level 3	(540,587)	(1,399,628)
Balance	$ 772,020	$ 411,718

NOTE 13 - SUBSEQUENT EVENTS (De

NOTE 13 - SUBSEQUENT EVENTS (Details) - Subsequent Event [Member]	1 Months Ended
	Oct. 31, 2016USD ($)shares
Common Stock Issued in Settlement of Notes Payable [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued | shares	29,511,799
Debt Conversion, Original Debt, Amount | $	$ 37,950
Conversion of Accrued Interest [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued | shares	848,490
Debt Conversion, Original Debt, Amount | $	$ 12,705